Figure 3.

The anti‐KLH IgG titre over time (pre‐ and post‐treatment) for animals treated with vehicle N = 30 (a), i.v. 50 mg·kg⁻¹ VIB4920 N = 12 (b), i.v. 150 mg·kg⁻¹ VIB4920 N = 24 (c), i.v. 300 mg·kg⁻¹ VIB4920 N = 24 (d), and s.c. VIB4920 (e) across all three studies; N = 6 for 150 mg·kg⁻¹ s.c., N = 12 for 125 mg·kg⁻¹ s.c., N = 12 for 250 mg·kg⁻¹ s.c. KLH immunisation was given on pre‐study Day −28 and 1 hr post‐VIB4920 administration on Day 8. IgG titres for VIB4920‐dosed groups were significantly different (P ≤ .05) for all groups, compared to vehicle, on Days 15, 18, 22, 29, 36, 43, and 50; one‐way ANOVA with Dunnetts multiple comparisons test with a single pooled variance or Kruskal–Wallis test with Dunns multiple comparisons test. IgG, immunoglobulin G; i.v., intravenous; KLH, keyhole limpet haemocyanin; s.c., subcutaneous